Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.09 EUR
−23.00 M EUR
2.23 M EUR
16.35 M
About OSE IMMUNOTHERAPEUTICS
Sector
CEO
Nicolas Poirier
Headquarters
Nantes
Website
Founded
2004
ISIN
FR0012127173
FIGI
BBG008891XD6
OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. It focuses on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation. The company was founded by Dominique Constantini on November 17, 2004 and is headquartered in Nantes, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OSE is 8.89 EUR — it has increased by 2.42% in the past 24 hours. Watch OSE IMMUNOTHERAPEUTICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange OSE IMMUNOTHERAPEUTICS stocks are traded under the ticker OSE.
OSE stock has fallen by −2.84% compared to the previous week, the month change is a −13.86% fall, over the last year OSE IMMUNOTHERAPEUTICS has showed a 99.78% increase.
We've gathered analysts' opinions on OSE IMMUNOTHERAPEUTICS future price: according to them, OSE price has a max estimate of 14.00 EUR and a min estimate of 10.80 EUR. Watch OSE chart and read a more detailed OSE IMMUNOTHERAPEUTICS stock forecast: see what analysts think of OSE IMMUNOTHERAPEUTICS and suggest that you do with its stocks.
OSE stock is 5.23% volatile and has beta coefficient of 0.95. Track OSE IMMUNOTHERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is OSE IMMUNOTHERAPEUTICS there?
Today OSE IMMUNOTHERAPEUTICS has the market capitalization of 193.39 M, it has decreased by −2.25% over the last week.
Yes, you can track OSE IMMUNOTHERAPEUTICS financials in yearly and quarterly reports right on TradingView.
OSE IMMUNOTHERAPEUTICS is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
OSE net income for the last half-year is 57.17 M EUR, while the previous report showed −11.14 M EUR of net income which accounts for 613.10% change. Track more OSE IMMUNOTHERAPEUTICS financial stats to get the full picture.
No, OSE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 55.00 employees. See our rating of the largest employees — is OSE IMMUNOTHERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OSE IMMUNOTHERAPEUTICS EBITDA is 36.34 M EUR, and current EBITDA margin is −1.30 K%. See more stats in OSE IMMUNOTHERAPEUTICS financial statements.
Like other stocks, OSE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OSE IMMUNOTHERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OSE IMMUNOTHERAPEUTICS technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OSE IMMUNOTHERAPEUTICS stock shows the buy signal. See more of OSE IMMUNOTHERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.